Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a research note published on Monday morning,Benzinga reports. They currently have a $30.00 target price on the stock.

Several other analysts have also recently weighed in on the stock. Craig Hallum started coverage on shares of Compass Therapeutics in a report on Friday, February 13th. They issued a “buy” rating and a $15.00 price target on the stock. Wall Street Zen cut shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Raymond James Financial reiterated an “outperform” rating on shares of Compass Therapeutics in a research report on Thursday, March 5th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Compass Therapeutics in a research report on Thursday, March 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Therapeutics in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.20.

Compass Therapeutics Trading Down 64.4%

CMPX stock opened at $1.79 on Monday. The firm’s 50-day moving average price is $5.46 and its two-hundred day moving average price is $5.28. Compass Therapeutics has a 12-month low of $1.61 and a 12-month high of $6.88. The stock has a market capitalization of $322.36 million, a price-to-earnings ratio of -4.16 and a beta of 1.49.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. Equities analysts predict that Compass Therapeutics will post -0.41 EPS for the current year.

Institutional Investors Weigh In On Compass Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CMPX. Strs Ohio purchased a new stake in Compass Therapeutics in the first quarter worth about $34,000. Creative Planning purchased a new stake in Compass Therapeutics in the second quarter worth about $30,000. XTX Topco Ltd purchased a new stake in Compass Therapeutics in the second quarter worth about $84,000. Invesco Ltd. grew its holdings in Compass Therapeutics by 58.1% in the second quarter. Invesco Ltd. now owns 58,735 shares of the company’s stock worth $153,000 after purchasing an additional 21,578 shares during the period. Finally, Adage Capital Partners GP L.L.C. grew its holdings in Compass Therapeutics by 11.3% in the second quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after purchasing an additional 449,868 shares during the period. Hedge funds and other institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.